Evidence map›Paper›PMID 31907973›Full record

ArticleJournal of clinical laboratory analysis2020

Expression patterns of CD28 and CTLA-4 in early, chronic, and untreated rheumatoid arthritis.

Mariel García-Chagollán, Iris Yolanda Ledezma-Lozano, Jorge Hernández-Bello, Pedro Ernesto Sánchez-Hernández, Sergio Ramón Gutiérrez-Ureña, José Francisco Muñoz-Valle

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Differences in IDO1Frontiers in immunology · 2024
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mariel García-ChagollánInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Iris Yolanda Ledezma-LozanoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Jorge Hernández-BelloInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Pedro Ernesto Sánchez-HernándezLaboratorio de Inmunología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Sergio Ramón Gutiérrez-UreñaServicio de Reumatología, OPD Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, México.
José Francisco Muñoz-ValleInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.ORCID https://orcid.org/0000-0002-2272-9260
Universidad de Guadalajara · MXHospital Civil de Guadalajara · MX

Funding

Consejo Nacional de Ciencia y Tecnología Grant A1-S-8774 (CONACYT Ciencia Básica
6 · The paper itself

Abstract

backgroundT-cell activation pathways have been proposed as trigger mechanisms in the pathogenesis of rheumatoid arthritis (RA). CD28 and CTLA-4 play major roles in regulating the stimulatory and inhibitory co-signals in T cells.

objectiveTo analyze the association between soluble and surface expression of CD28 and CTLA-4 with the clinical parameters of RA patients.

methodsA total of 35 RA patients classified as early RA (n = 14), chronic RA (n = 14), and untreated RA (n = 7), as well as 7 age- and sex-matched control subjects (CS) were included. Surface expression of CD28 and CTLA-4 on T cells was evaluated by flow cytometry. Soluble levels of CD28 (sCD28), CTLA-4 (sCTLA-4), and anti-CCP antibodies were measured by ELISA.

resultsA significant lower percentage of CD8 + T cells positive to CD28 (CS = 64.9% vs RA = 42.7%, P = .04), and diminished surface expression of CD28 (CS: MFI = 122.9 vs RA: MFI = 33.1, P = .006), were found in chronic RA patients compared to CS. Higher sCD28 were observed in early RA patients compared with chronic RA patients (P < .05). sCTLA-4 was found increased in untreated RA patients compared to early RA patients (P < .05). sCD28 concentration correlated with anti-CCP levels (rho = -0.12; P = .032). The soluble and surface expressions of CTLA-4 were not associated with RA clinical parameters.

conclusionsIn RA, the percentage of CD8 + CD28+ T cells decreases and expresses fewer membrane CD28 than CS. sCD28 levels are lower in chronic RA and are associated negatively with anti-CCP levels. sCTLA 4 levels are lower in early RA patients than in untreated RA patients.

Indexed as

AdultAgedAnti-Citrullinated Protein AntibodiesArthritis, RheumatoidBiomarkersCase-Control StudiesCD28 AntigensCD8-Positive T-LymphocytesChronic DiseaseCTLA-4 AntigenFemaleHumansMaleMiddle AgedAnti-Citrullinated Protein AntibodiesBiomarkersCD28 AntigensCTLA-4 AntigenCTLA4 protein, humanCD28CTLA4Rheumatoid arthritis

Identifiers

PMID31907973
PMCPMC7246387
OpenAlexW2999357537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.